Abstract
Background
Persistent Polyclonal Binucleated B-cell Lymphocytosis (PPBL) is characterized by a chronic polyclonal B-cell lymphocytosis with binucleated lymphocytes and a polyclonal increase in serum immunoglobulin-M. Cytogenetic is characterized by the presence of a supernumerary isochromosome +i(3)(q10), premature chromosome condensation and chromosomal instability. Outcome of PPBL patients is mostly benign, but subsequent malignancies could occur. The aim of our study is to provide an update of clinical and cytogenetic characteristics of our large cohort of PPBL patients, to describe subsequent malignancies occurring during the follow-up, and to investigate the role of the long arm of chromosome 3 in PPBL.
Results
We analyzed clinical, biological and cytogenetic characteristics (conventional cytogenetic analysis and fluorescent in situ hybridization) of 150 patients diagnosed with PPBL. We performed high-resolution SNP arrays in 10 PPBL patients, comparing CD19+ versus CD19− lymphoid cells. We describe the cytogenetic characteristics in 150 PPBL patients consisting in the presence of supernumerary isochromosome +i(3)(q10) (59 %) and chromosomal instability (55 %). In CD19+ B-cells, we observed recurrent copy number aberrations of 143 genes with 129 gains (90 %) on 3q and a common minimal amplified genomic region in the MECOM gene. After a median follow-up of 60 months, we observed the occurrence of 12 subsequent malignancies (12 %), 6 solid tumors and 6 Non-Hodgkin’s Lymphomas, and 6 monoclonal gammopathies of undetermined significance (MGUS), requiring a long-term clinical follow-up.
Conclusions
Our clinical and cytogenetic observations lead us to hypothesize that isochromosome 3q, especially MECOM abnormality, could play a key role in PPBL.
Keywords: Persistent Polyclonal Binucleated B-cell Lymphocytosis, MECOM, SNP array
Background
Persistent Polyclonal Binucleated B-cell Lymphocytosis (PPBL) is characterized by a chronic, stable and asymptomatic lymphocytosis with binucleated lymphocytes [1]. Binucleated lymphocytes are not specific for PPBL and can be observed in patients with multiple sclerosis treated by natalizumab [2] or after accidental exposure to ionizing radiation. In the peripheral blood, a polyclonal increase of memory B cells (CD19+, CD5−, CD27+, IgM+, IgD+) is usually associated with a polyclonal increase in serum immunoglobulin-M (IgM) [3–6]. PPBL is characterized by a recurrent supernumerary isochromosome +i(3)(q10), a premature chromosome condensation (PCC) and a chromosomal instability [3, 4]. PPBL evolution is benign in most cases, but non-Hodgkin’s lymphomas and solid tumors (pulmonary blastoma) were previously and rarely described [7, 8]. In this study, we report the follow-up and the cytogenetic characteristics of a large cohort of 150 PPBL patients. We report the occurrence of subsequent malignancies in up to 12 % of patients contrasting with previous studies. Strong association between supernumerary isochromosome 3q, chromosomal instability and PPBL led us to study more extensively the role of the long arm of chromosome 3 using SNP arrays in 10 patients. We observed that the MECOM gene, located on 3q26, was recurrently amplified in B-cells of PPBL patients.
Patients and methods
Patients
PPBL was diagnosed from the persistence during three months of binucleated lymphocytes on a peripheral blood film. Patients were included after written informed consent, in accordance with the Declaration of Helsinki and with institutional guidelines and after approval of the French relevant competent authorities and ethics committees (Committee of Protection of Individuals (CPP), Advisory Committee on the Processing of Information for Medical Research (CCTIRS) and the French National Commission for Data Protection (CNIL)).
Using multiparameter flow cytometry (MFC), B-cells were polyclonal in all cases, based on the expression of CD19 and the absence of a restriction of expression of light chain of immunoglobulin. Blood smears were reviewed in the same laboratory.
Conventional cytogenetic analysis (CCA)
Blood samples were collected on heparin tubes at the time of diagnosis and during the follow-up. All samples were processed in the same laboratory. CCA was performed as previously described [3]. As previously described [9], chromosomal instability was defined as the gain and/or loss of whole chromosomes or chromosomal segments at a higher rate in tumor cell population compared to normal cells.
Fluorescent in situ hybridization (FISH)
FISH was performed in order to detect supernumerary isochromosome +i(3)(q10) in metaphase and interphase cells using alpha-satellite chromosome 3 specific probes and Bcl6 (3q27) specific probes (Vysis™, USA). One hundred metaphases and three hundred interphases cells were analyzed per patient.
SNP array
SNP arrays were performed using Affymetrix™ Cytogenetics Whole-Genome 2.7M Arrays® (Affymetrix™, USA). All samples were processed in the same laboratory. Patients were selected according to the availability of sufficient fresh cells (diagnosis) or frozen cells (follow-up). Immunomagnetic sorting was performed on whole blood samples or on thawed cells in order to purify CD19+ cells (Miltenyi™ AutoMACS Pro Separator®, Bergisch Gladbach, Germany). The two fractions (CD19+ positive and CD19− negative selection) were kept and the purity was checked to be >95 % by flow cytometry. The DNA was extracted from the two fractions using Gentra Puregene Blood Kit® (Qiagen™, Hilden, Germany). Hybridization of the DNA on chips was performed according the manufacturer’s instructions. Chips were analyzed using Affymetrix™ Chromosome Analysis Suite® (ChASver 1.0.1). Database of annotations was NetAffx Build 30. Quality controls of the chips were set up according Affymetrix™ recommendations (SNP-QC ≥ 1.1 and MAPD (CN-QC) ≤ 0.27). Copy Number Aberrations (CNA) were called according user-defined thresholds (Copy Number (CN) markers >50 and size >25 kb). The Database of Genomic Variants (DGV, http://projects.tcag.ca/variation/) was consulted to determine whether CNA corresponded to genomic variants. Number and size of Copy Number Aberrations (CNAs) were analyzed and compared between patients and between CD19+ and CD19− cells. CNA are called recurrent when at least two patients present the same CNA. Mosaicism phenomenon was detected in case of allele frequencies between disomic and trisomic states.
Results
PPBL was diagnosed in 150 untreated patients, whose main characteristics are described in Table 1. Sixty-nine percent of cases showed an absolute lymphocytosis >4 × 109/L, with a mean percentage of binucleated lymphocytes at 3.9 % (1–40). Median follow-up was 60 months (1–402) and median overall survival was not reached. Eighteen patients (12 %) developed subsequent malignancies, among which nine cases were previously described (non Hodgkin’s lymphomas (NHL) in three cases, solid tumors in two cases and monoclonal gammopathies of undetermined significance (MGUS) in 4 cases) [10]. Among the 18 patients, six patients developed solid tumors with a mean time of occurrence of 87 months (3–156) (4 pulmonary cancers, 1 breast cancer and 1 cervical carcinoma). Twelve patients (8 %) developed hematological malignancies. Six cases of MGUS (IgM) (4 %) and NHL (4 %) occurred with a mean time of 75 months (0–264) and 58 months (0–120), respectively. Four patients developed a diffuse large B-cell lymphoma and 2 patients a splenic marginal zone lymphoma (Table 2 for details). Among these 18 cases, 17 patients were chronic smokers. These data strongly lead us to consider PPBL as a premalignant state requiring a long-term follow-up.
Table 1.
Characteristics and follow-up of 150 patients with PPBL
| Age (years), Mean (min–max) | 40 (18.9–66.2) | ||
| Sex (M/F) | 26 (17 %)/124 (83 %) | ||
| Tobacco consumption | 130/145 (90 %) | ||
| Clinical presentation | |||
| Lymph node(s) | 10/108 (9 %) | ||
| Splenomegaly | 19/106 (18 %) | ||
| Hepatomegaly | 2/108 (2 %) | ||
| Hemogram, Mean (min–max) | |||
| White blood cells (109/L) | 12.8 (7–44.8) | ||
| Hemoglobin (g/dL) | 13.8 (10.1–16.9) | ||
| Platelets (109/L) | 228 (83–380) | ||
| Lymphocytosis (109/L) | 6.5 (2.2–41) | ||
| Binucleated Lymphocytes (% of lymphocytes) | 3.9 (1–40) | ||
| IgM (g/L), Mean (min–max) | 7.8 (2.17–20) | ||
| HLA DR7 positive | 40/52 (77 %) | ||
| Multiparameter Flow Cytometry—Mean (min–max) | |||
| CD19 (%) | 50.4 (7–83) | ||
| Cytogenetics | Diagnosis | Follow-up | |
| +i(3)(q10) positive by karyotype | 50/140 (36 %) | 20/32 (63 %) | |
| +i(3)(q10) positive by FISH | 80/128 (63 %) | 24/26 (92 %) | |
| PCC positive | 35/140 (25 %) | 8/32 (25 %) | |
| Chromosomal instability | 76/140 (54 %) | 31/32 (97 %) | |
| Subsequent Malignancies | 18/150 (12 %) | ||
| MGUS | 6/150 (4 %) | ||
| Non-Hodgkin’s Lymphomas | 6/150 (4 %) | ||
| Solid tumors | 6/150 (4 %) |
Clinical and biological data were collected from 27 centers. Median follow-up was 60 months (1–402) with unreached median overall survival
MGUS monoclonal gammopathy of undetermined significance
Table 2.
Eighteen subsequent malignancies occurred in PPBL patients
| Patients | Delay between PPBL and subsequent malignancy’s diagnosis | Type of malignancy | Follow-up |
|---|---|---|---|
| UPN36 | 38 months | DLBCL | 56 months |
| UPN47 | 20 months | SMZL | +65 months |
| UPN57 | 92 months | DLBCL | 99 months |
| UPN63 | Diagnosis of PPBL and lymphoma was concomitant | DLBCL | +13 months |
| UPN71 | 77 months | SMZL | +86 months |
| UPN83 | 120 months | DLBCL | +131 months |
| UPN1 | 264 months | MGUS | +348 months |
| UPN10 | 144 months | MGUS | +148 months |
| UPN157 | 44 months | MGUS | +47 months |
| UPN118 | Diagnosis of PPBL and MGUS was concomitant | MGUS | +36 months |
| UPN163 | Diagnosis of PPBL and MGUS was concomitant | MGUS | +57 months |
| UPN105 | Diagnosis of PPBL and MGUS was concomitant | MGUS | +42 months |
| UPN5 | 96 months | Mammary carcinoma | +272 months |
| UPN6 | 3 months | Pulmonary carcinoma | 3 months |
| UPN70 | 22 months | Pulmonary carcinoma | +22 months |
| UPN86 | 132 months | Pulmonary carcinoma | +146 months |
| UPN160 | 114 months | Pulmonary carcinoma | 112 months |
| UPN67 | 156 months | Cervical carcinoma | +181 months |
Six patients developed solid tumors (4 pulmonary cancers, 1 breast cancer and 1 cervical carcinoma) and 6 patients hematological malignancies (diffuse large B-cell lymphoma (DLBCL) in 4 cases, splenic marginal zone lymphoma (SMZL) in 2 cases) and 6 patients monoclonal gammopathies of undetermined significance (MGUS) (IgM)
At diagnosis, CCA and FISH were performed in 140 and 128 patients, respectively. During the follow-up, CCA was performed in 32 patients (21 %). CCA and FISH detected no cytogenetic abnormality in 52/140 patients (37 %). Recurrent supernumerary isochromosome +i(3)(q10) was identified in 82/140 patients (59 %). PCC, arising from asynchronous mitotic activity in multinucleated cells, was observed concomitantly with +i(3)(q10) in 30/140 patients (21 %). By CCA, trisomy 8 and del(6q) were also detected either as recurrent abnormalities (2/140 and 5/140, respectively) or as non-recurrent abnormalities (9/140 and 4/140, respectively). Chromosomal instability was observed in 76/140 patients (54 %) and persisted in 31/32 patients (97 %) during follow-up.
To determine whether 3q could be implicated in PPBL pathogenesis, SNP arrays were performed in 10 patients (3 males, 7 females) with +i(3)(q10) in 9/10 patients (Table 3 for details). Written informed consents were obtained from the patients. The comparative analysis of sorted CD19+ and CD19− cells revealed that CNAs were observed predominantly in CD19+ B-cells on 3q (Table 4) with mosaicism phenomenon in 3 patients. Genetic instability was observed in all cases and predominantly in CD19+ B-cells. We observed 143 recurrent CNAs with 129 gains (90 %) on 3q of B-cells (Table 5). Interestingly, we identified with a high frequency (7/9 patients) partial or complete amplification of one particular genomic region located in 3q26.2. The size of this common minimal amplified region was 28 kilobases (85 copy number markers) located in coding region of MECOM gene (Fig. 1). This amplification was not detected in two patients (UPN147 and UPN136). In one of them (UPN147), no +i(3)(q10) was detected by CCA and/or FISH. Unfortunately, due to the mosaicism phenomenon, with less than 20 % of B-cells presenting +i(3)(q10), gain in MECOM gene has not been confirmed yet by other molecular studies, such as quantitative PCR.
Table 3.
Characteristics of the 10 patients analyzed by SNP arrays (UPN: Unique Patient Number)
| Patient | Karyotype | PCC (%) | FISH +i(3)(q10) (%) |
|---|---|---|---|
| UPN8b | 46–47,XX, +i(3)(q10) [3] /46,XX,del(2)(q22), −17, +mar [1] /45, X, −X [1] /46,XX [40] | Absent | Present (6 %) |
| UPN57a | 47,XY, +i(3)(q10) [5] /48,XY, +i(3)(q10), +12 [01]/46,XY,t(14;18)(q32;q22)[01]/47,XY,t(11;14)(q13;q32), +mar [01]/46,XY,add(3)(p26) [1] /47,XY, +22[01]/49,XY, +i(3)(q10), +8, +mar[01]/46,XY [39] | Absent | Present (7 %) |
| UPN136a | 46,XX [48]/PCC [2] | Present (4 %) | Present (4 %) |
| UPN71c | 47,XX, +X,del(6)(q15q26)[01]/46,XX,del(6)(q15q26),der(6)t(6;6)(q21;q23)[08]/46,XX,del(1)(q12),der(14)t(1;14)(p22;q32)[02]/46,XX[09] | Absent | Present (2 %) |
| UPN127b | 47,XY, +i(3)(q10) [3] /46,X,der(Y)t(Y;?)(q12;?) [3] /46,XY [12] | Absent | Present (12 %) |
| UPN138a | 46,XX,del(6)(q21q24) [6] /46,XX,der(8)t(3;8)(q11;q11),der(17)t(17;?)(p11;?) [2] /46,XX,del(17)(p11) [2] /46,XX,t(1;6)(q24;q21) [1] /46,XX,der(14)t(14;?)(p25;?) [1] /46,XX,dup(3)(p13p26) [1] /46,XX,der(4)t(4;?)(p16;?) [1] /46,XX [26] | Absent | Present (11 %) |
| UPN99a | 47,XX, +18 [2] /47,XX, +3 [1] /46,XX [37]/PCC [1] | Present (2 %) | Present (4 %) |
| UPN147a | 46,XX [50] | Absent | Absent |
| UPN73a | 46,XX [50] | Absent | Present (1.4 %) |
| UPN105a | 46,XY [46]/46,XY [cp 4] | Absent | Present (3 %) |
Depending on the quality of extracted DNA, we performed DNA arrays on aboth CD19+ and CD19− cells in 7 patients, bCD19+ cells in 2 patients and cCD19− cells in 1 patient. CCA and/or FISH detected +i(3)(q10) in 9/10 patients
PCC premature chromosome condensation
Table 4.
Repartition of CNAs observed in CD19− and CD19+ cells. CD19+ cells presented twice as many CNAs as CD19− [83 CNAs (12–218) versus 42 (3–184)]
| CD19− | CNAs—Total (gains/losses) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Chromosome | UPN73 | UPN71 | UPN57 | UPN136 | UPN138 | UPN99 | UPN147 | UPN105 | Mean |
| 1 | 2 (2/0) | 0 (0/0) | 4 (1/3) | 1 (0/1) | 3 (3/0) | 1 (0/1) | 0 (0/0) | 17 (0/17) | 3.5 (0.7/2.8) |
| 2 | 3 (1/2) | 1 (1/0) | 0 (0/0) | 2 (0/2) | 2 (2/0) | 0 (0/0) | 0 (0/0) | 24 (0/24) | 4.0 (0.5/3.5) |
| 3 | 2 (1/1) | 0 (0/0) | 3 (3/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 8 (1/7) | 1.6 (0.6/1.0) |
| 3p | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0.0 (0.0/0.0) |
| 3q | 2 (1/1) | 0 (0/0) | 3 (3/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 8 (1/7) | 1.6 (0.6/1.0) |
| 4 | 0 (0/0) | 0 (0/0) | 0 (0/0) | 2 (1/1) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 30 (1/29) | 4.1 (0.4/3.7) |
| 5 | 0 (0/0) | 1 (0/1) | 1 (0/1) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 0 (0/0) | 15 (0/15) | 2.3 (0.1/2.2) |
| 6 | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 0 (0/0) | 11 (0/11) | 1.5 (0.1/1.4) |
| 7 | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 1 (1/0) | 12 (0/12) | 1.8 (0.3/1.5) |
| 8 | 1 (0/1) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 3 (3/0) | 0 (0/0) | 0 (0/0) | 6 (0/6) | 1.4 (0.5/0.9) |
| 9 | 0 (0/0) | 4 (0/4) | 3 (0/3) | 0 (0/0) | 4 (2/2) | 1 (1/0) | 0 (0/0) | 7 (0/7) | 2.4 (0.4/2.0) |
| 10 | 1 (1/0) | 1 (0/1) | 1 (0/1) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 1 (1/0) | 7 (0/7) | 1.5 (0.4/1.1) |
| 11 | 0 (0/0) | 2 (1/1) | 0 (0/0) | 0 (0/0) | 2 (2/0) | 0 (0/0) | 1 (0/1) | 10 (0/10) | 1.9 (0.4/1.5) |
| 12 | 2 (2/0) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 0 (0/0) | 8 (1/7) | 1.5 (0.5/1.0) |
| 13 | 0 (0/0) | 0 (0/0) | 2 (0/2) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 0 (0/0) | 8 (1/7) | 1.4 (0.1/1.3) |
| 14 | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 6 (1/5) | 0.8 (0.1/0.7) |
| 15 | 2 (2/0) | 1 (1/0) | 1 (0/1) | 2 (0/2) | 2 (1/1) | 0 (0/0) | 1 (1/0) | 4 (1/3) | 1.6 (0.9/0.7) |
| 16 | 1 (1/0) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 3 (1/2) | 0 (0/0) | 0 (0/0) | 1 (0/1) | 0.8 (0.4/0.4) |
| 17 | 0 (0/0) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 0 (0/0) | 4 (2/2) | 0.8 (0.4/0.4) |
| 18 | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 0 (0/0) | 1 (0/1) | 0.2 (0.2/0.1) |
| 19 | 0 (0/0) | 1 (0/1) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1 (0/1) | 1 (0/1) | 1 (0/1) | 0.5 (0.0/0.5) |
| 20 | 1 (1/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0.3 (0.3/0.0) |
| 21 | 1 (0/1) | 1 (0/1) | 1 (0/1) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1 (0/1) | 0.5 (0.0/0.5) |
| 22 | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 1 (1/0) | 0.3 (0.3/0.0) |
| X | 1 (1/0) | 7 (6/1) | 13 (13/0) | 1 (0/1) | 25 (24/1) | 0 (0/0) | 2 (1/1) | 1 (0/1) | 6.2 (5.6/0.6) |
| Y | 1 (1/0) | 1 (1/0) | 2 (0/2) | 0 (0/0) | 2 (2/0) | 0 (0/0) | 0 (0/0) | 1 (0/1) | 0.9 (0.5/0.4) |
| Total | 18 (13/5) | 20 (10/10) | 33 (18/15) | 10 (3/7) | 55 (48/7) | 3 (1/2) | 9 (6/3) | 184 (9/175) | 41.5 (13.5/28) |
| CD19+ | CNAs—total (gains/losses) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Chromosome | UPN73 | UPN8 | UPN57 | UPN136 | UPN127 | UPN138 | UPN99 | UPN147 | UPN105 | Mean |
| 1 | 20 (19/1) | 0 (0/0) | 0 (0/0) | 4 (0/4) | 0 (0/0) | 0 (0/0) | 5 (4/1) | 8 (1/7) | 0 (0/0) | 5.0 (3.6/1.4) |
| 2 | 22 (22/0) | 2 (1/1) | 0 (0/0) | 2 (0/2) | 0 (0/0) | 1 (0/1) | 3 (3/0) | 12 (1/11) | 0 (0/0) | 5.7 (3.9/1.8) |
| 3 | 20 (19/1) | 4 (4/0) | 26 (25/1) | 0 (0/0) | 46 (46/0) | 1 (1/0) | 2 (2/0) | 5 (0/5) | 113 (113/0) | 25.0 (24.2/0.8) |
| 3p | 11 (11/0) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1.8 (1.7/0.1) |
| 3q | 9 (8/1) | 4 (4/0) | 25 (25/0) | 0 (0/0) | 46 (46/0) | 1 (1/0) | 2 (2/0) | 5 (0/5) | 113 (113/0) | 23.2 (22.6/0.7) |
| 4 | 9 (9/0) | 0 (0/0) | 2 (0/2) | 5 (1/4) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 10 (1/9) | 0 (0/0) | 4.0 (2.3/1.7) |
| 5 | 14 (13/1) | 0 (0/0) | 0 (0/0) | 2 (0/2) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 5 (0/5) | 1 (0/1) | 3.4 (2.4/1.0) |
| 6 | 10 (10/0) | 1 (1/0) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 1 (1/0) | 1 (1/0) | 5 (1/4) | 0 (0/0) | 2.9 (2.3/0.6) |
| 7 | 12 (12/0) | 1 (0/1) | 0 (0/0) | 1 (0/1) | 1 (0/1) | 0 (0/0) | 1 (1/0) | 6 (1/5) | 0 (0/0) | 2.4 (1.6/0.8) |
| 8 | 13 (11/2) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1 (0/1) | 1 (1/0) | 2 (0/2) | 0 (0/0) | 2.3 (1.8/0.5) |
| 9 | 14 (14/0) | 0 (0/0) | 0 (0/0) | 4 (0/4) | 0 (0/0) | 5 (0/5) | 1 (1/0) | 4 (1/3) | 0 (0/0) | 3.8 (2.4/1.4) |
| 10 | 8 (8/0) | 0 (0/0) | 0 (0/0) | 3 (0/3) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1.6 (1.2/0.4) |
| 11 | 9 (9/0) | 0 (0/0) | 0 (0/0) | 2 (0/2) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 7 (0/7) | 0 (0/0) | 2.8 (1.8/1.0) |
| 12 | 5 (5/0) | 1 (0/1) | 2 (0/2) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 1 (1/0) | 8 (1/7) | 0 (0/0) | 2.7 (1.6/1.1) |
| 13 | 4 (4/0) | 0 (0/0) | 1 (0/1) | 2 (0/2) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 2 (0/2) | 1 (1/0) | 1.3 (0.7/0.6) |
| 14 | 3 (3/0) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 2 (2/0) | 0 (0/0) | 0 (0/0) | 1.1 (1.0/0.1) |
| 15 | 5 (5/0) | 0 (0/0) | 1 (1/0) | 1 (0/1) | 2 (0/2) | 1 (0/1) | 0 (0/0) | 2 (1/1) | 1 (1/0) | 1.8 (1.2/0.6) |
| 16 | 2 (2/0) | 0 (0/0) | 0 (0/0) | 2 (0/2) | 1 (1/0) | 2 (0/2) | 0 (0/0) | 1 (1/0) | 1 (0/1) | 1.6 (1.0/0.6) |
| 17 | 4 (4/0) | 0 (0/0) | 0 (0/0) | 1 (0/1) | 1 (1/0) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 0.9 (0.8/0.1) |
| 18 | 5 (5/0) | 1 (1/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 3 (3/0) | 1 (1/0) | 1 (0/1) | 0 (0/0) | 1.9 (1.8/0.1) |
| 19 | 1 (1/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 0.4 (0.2/0.2) |
| 20 | 5 (5/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 2 (2/0) | 1 (1/0) | 0 (0/0) | 1.2 (1.2/0.0) |
| 21 | 1 (0/1) | 0 (0/0) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 1 (0/1) | 0 (0/0) | 2 (0/2) | 0 (0/0) | 0.6 (0.0/0.6) |
| 22 | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) | 1 (1/0) | 0 (0/0) | 0.3 (0.3/0.0) |
| X | 28 (27/1) | 1 (0/1) | 1 (1/0) | 7 (5/2) | 2 (2/0) | 5 (4/1) | 1 (1/0) | 5 (3/2) | 0 (0/0) | 7.0 (6.2/0.2) |
| Y | 4 (4/0) | 1 (1/0) | 0 (0/0) | 6 (6/0) | 0 (0/0) | 14 (14/0) | 2 (2/0) | 0 (0/0) | 0 (0/0) | 3.0 (3.0/0.0) |
| Total | 218 (211/7) | 12 (8/4) | 34 (27/7) | 44 (12/32) | 55 (51/4) | 37 (24/13) | 24 (23/1) | 89 (15/74) | 117 (115/2) | 82.7 (66.6/16.1) |
28 % of CNAs (0–97 %) were located on 3q in CD19+ cells compared to 5 % (0–11 %) in CD19− cells (data not shown)
Table 5.
Recurrent Copy Number Aberrations (CNA) in CD19+ B-cells. 143 CNA had been observed
| Chr | Cytoregion | Recurrence | Recurrence including mosaicism | CN state | Gene | Minimal common size (kbp) | Genic region: total (T) Exonic (E) Intronic (I) |
CNA reported in DGV |
|---|---|---|---|---|---|---|---|---|
| 1 | p33 | 2 | 2 | Loss | FAF1 | 31 | I | No |
| 1 | p32.2 | 2 | 2 | Gain | C1orf168 | 50.2 | E/I | No |
| 2 | p23.2 | 2 | 2 | Gain | ALK | 62 | E/I | Yes |
| 2 | q21.2–q21.3 | 2 | 2 | Gain | MGAT5 | 72 | E/I | No |
| 3 | p24.2 | 2 | 2 | Gain | THRB | 55.7 | I | No |
| 3 | q11.2 | 2 | 3 | Gain | LOC255025 | 50 | E/I | No |
| 3 | q12.2 | 2 | 3 | Gain | ABI3BP | 143 | E/I | Yes |
| 3 | q13.13 | 2 | 3 | Gain | DZIP3 | 10.6 | I | No |
| 3 | q13.31 | 2 | 3 | Gain | ZBTB20 | 39 | I | No |
| 3 | q13.31 | 2 | 3 | Gain | GAP43 | 399 | T | No |
| 3 | q13.31 | 2 | 3 | Gain | LSAMP | 53 | I | No |
| 3 | q13.33 | 2 | 3 | Gain | TMEM39A | 176 | T | No |
| 3 | q13.33 | 2 | 3 | Gain | KTELC1 | 176 | T | No |
| 3 | q13.33 | 2 | 3 | Gain | C3orf1 | 176 | T | No |
| 3 | q13.33 | 2 | 3 | Gain | CD80 | 176 | T | No |
| 3 | q13.33 | 2 | 3 | Gain | ADPRH | 176 | T | No |
| 3 | q21.1 | 2 | 3 | Gain | HSPBAP1 | 101 | E/I | No |
| 3 | q21.1 | 2 | 4 | Gain | DIRC2 | 101 | T | No |
| 3 | q21.1 | 2 | 4 | Gain | LOC100129550 | 101 | T | Yes |
| 3 | q21.1 | 2 | 4 | Gain | SEC22A | 114 | T | No |
| 3 | q21.1 | 2 | 4 | Gain | PTPLB | 125 | T | No |
| 3 | q21.1 | 3 | 4 | Gain | MYLK | 70 | E/I | No |
| 3 | q21.1 | 2 | 4 | Gain | CCDC14 | 121 | E/I | Yes |
| 3 | q21.2 | 2 | 4 | Gain | KALRN | 169 | T | No |
| 3 | q21.2 | 2 | 4 | Gain | UMPS | 169 | T | No |
| 3 | q21.2 | 2 | 4 | Gain | ZNF148 | 164 | E/I | Yes |
| 3 | q21.2 | 2 | 4 | Gain | ALDH1L1 | 171 | E/I | No |
| 3 | q21.3 | 3 | 4 | Gain | TXNRD3IT1 | 299 | E/I | No |
| 3 | q21.3 | 3 | 4 | Gain | CHCHD6 | 299 | E/I | No |
| 3 | q21.3 | 2 | 4 | Gain | KLHDC6 | 95 | T | No |
| 3 | q21.3 | 2 | 4 | Gain | RUVBL1 | 211 | E/I | Yes |
| 3 | q21.3 | 2 | 4 | Gain | EEFSEC | 211 | E/I | Yes |
| 3 | q21.3 | 2 | 4 | Gain | GATA2 | 76 | E/I | Yes |
| 3 | q21.3 | 3 | 4 | Gain | LOC90246 | 76 | T | Yes |
| 3 | q21.3 | 2 | 4 | Gain | C3orf27 | 120.7 | T | Yes |
| 3 | q21.3 | 2 | 4 | Gain | TMCC1 | 268 | T | No |
| 3 | q21.3 | 2 | 4 | Gain | COL6A4P2 | 131 | T | Yes |
| 3 | q22.1 | 2 | 4 | Gain | MRPL3 | 62 | E/I | Yes |
| 3 | q22.1 | 2 | 4 | Gain | SNORA58 | 62 | T | Yes |
| 3 | q22.1 | 3 | 5 | Gain | CPNE4 | 46 | I | Yes |
| 3 | q22.1 | 2 | 4 | Gain | CPNE4 | 155 | E/I | Yes |
| 3 | q22.1 | 2 | 4 | Gain | TMEM108 | 120 | I | Yes |
| 3 | q22.1 | 2 | 4 | Gain | TOPBP1 | 69 | E/I | No |
| 3 | q22.1 | 2 | 4 | Gain | RYK | 225 | T | No |
| 3 | q22.1 | 2 | 4 | Gain | ANAPC13 | 197 | T | Yes |
| 3 | q22.1 | 2 | 4 | Gain | CEP63 | 197 | T | Yes |
| 3 | q22.2 | 2 | 4 | Gain | EPHB1 | 144 | E/I | No |
| 3 | q22.2 | 2 | 4 | Gain | PPP2R3A | 85 | E/I | No |
| 3 | q22.3 | 2 | 4 | Gain | SOX14 | 925 | T | No |
| 3 | q22.3 | 3 | 4 | Gain | CLDN18 | 121 | T | Yes |
| 3 | q22.3 | 2 | 4 | Gain | ARMC8 | 77 | E/I | Yes |
| 3 | q22.3 | 2 | 4 | Gain | TXNDC6 | 77 | E/I | Yes |
| 3 | q22.3 | 2 | 4 | Gain | ESYT3 | 202.7 | E/I | No |
| 3 | q22.3 | 2 | 4 | Gain | CEP70 | 202.7 | T | No |
| 3 | q22.3 | 2 | 4 | Gain | FAIM | 202.7 | T | No |
| 3 | q22.3 | 2 | 4 | Gain | PIK3CB | 202.7 | E/I | No |
| 3 | q22.3 | 3 | 4 | Gain | LOC729627 | 193 | T | No |
| 3 | q22.3 | 3 | 4 | Gain | LOC389151 | 193 | T | No |
| 3 | q22.3 | 3 | 4 | Gain | FLJ46210 | 193 | T | No |
| 3 | q22.3 | 3 | 4 | Gain | BPESC1 | 193 | T | No |
| 3 | q22.3 | 2 | 4 | Gain | PISRT1 | 319 | T | No |
| 3 | q23 | 2 | 4 | Gain | MRPS22 | 89 | E/I | No |
| 3 | q23 | 2 | 4 | Gain | COPB2 | 89 | T | No |
| 3 | q23 | 3 | 4 | Gain | NMNAT3 | 277.8 | E/I | No |
| 3 | q23 | 4 | 5 | Gain | CLSTN2 | 46 | I | Yes |
| 3 | q23 | 2 | 4 | Gain | TRIM42 | 443 | T | Yes |
| 3 | q23 | 2 | 4 | Gain | SLC25A36 | 443 | T | Yes |
| 3 | q24 | 2 | 4 | Gain | SLC9A9 | 138 | E/I | Yes |
| 3 | q24 | 2 | 4 | Gain | PLSCR4 | 47 | E/I | No |
| 3 | q24 | 2 | 4 | Gain | PLSCR5 | 69 | T | No |
| 3 | q24 | 2 | 4 | Gain | AGTR1 | 194 | E/I | No |
| 3 | q25.1 | 2 | 4 | Gain | P2RY13 | 74 | E/I | No |
| 3 | q25.1 | 2 | 4 | Gain | MED12L | 74 | E/I | No |
| 3 | q25.1 | 2 | 4 | Gain | P2RY13 | 74 | T | No |
| 3 | q25.2 | 2 | 4 | Gain | SGEF | 364 | E/I | Yes |
| 3 | q25.2–q25.31 | 3 | 4 | Gain | MME | 87.4 | E/I | No |
| 3 | q25.32 | 2 | 4 | Gain | VEPH1 | 78 | E/I | Yes |
| 3 | q25.32 | 2 | 4 | Gain | C3orf55 | 78 | E/I | No |
| 3 | q25.32 | 3 | 4 | Gain | MLF1 | 50 | E/I | No |
| 3 | q26.1 | 2 | 4 | Gain | C3orf57 | 120.6 | E/I | No |
| 3 | q26.1 | 2 | 4 | Gain | OTOL1 | 120.6 | T | No |
| 3 | q26.1 | 3 | 4 | Gain | SI | 747 | T | No |
| 3 | q26.1 | 3 | 4 | Gain | BCHE | 329 | E/I | No |
| 3 | q26.1 | 2 | 4 | Gain | ZBBX | 307 | T | No |
| 3 | q26.2 | 6 | 7 | Gain | MDS1 | 28 | E/I | No |
| 3 | q26.2 | 2 | 4 | Gain | TERC | 59 | T | Yes |
| 3 | q26.2 | 2 | 4 | Gain | ARPM1 | 59 | T | Yes |
| 3 | q26.2 | 2 | 4 | Gain | MYNN | 59 | T | Yes |
| 3 | q26.2 | 2 | 4 | Gain | LRRC34 | 59 | E/I | Yes |
| 3 | q26.2 | 3 | 5 | Gain | TNIK | 31 | E/I | No |
| 3 | q26.31 | 2 | 4 | Gain | NLGN1 | 125 | I | Yes |
| 3 | q26.31 | 2 | 4 | Gain | NLGN1 | 64 | E/I | No |
| 3 | q26.31 | 2 | 4 | Gain | NAALADL2 | 113 | E/I | Yes |
| 3 | q26.32 | 2 | 4 | Gain | TBL1XR1 | 60 | E/I | No |
| 3 | q26.32 | 2 | 4 | Gain | KCNMB2 | 121 | E/I | No |
| 3 | q26.33 | 2 | 4 | Gain | USP13 | 59 | E/I | No |
| 3 | q26.33 | 2 | 4 | Gain | PEX5L | 81 | E/I | No |
| 3 | q26.33 | 2 | 4 | Gain | CCDC39 | 118 | E/I | Yes |
| 3 | q27.1 | 2 | 4 | Gain | YEATS2 | 112 | E/I | No |
| 3 | q27.1 | 2 | 4 | Gain | MAP6D1 | 112 | T | No |
| 3 | q27.1 | 2 | 4 | Gain | PARL | 112 | E/I | No |
| 3 | q27.2 | 2 | 4 | Gain | VPS8 | 218 | E/I | No |
| 3 | q27.2 | 2 | 4 | Gain | ETV5 | 157 | T | No |
| 3 | q27.2 | 2 | 4 | Gain | DGKG | 157 | E/I | No |
| 3 | q27.3 | 2 | 4 | Gain | CRYGS | 110 | E/I | No |
| 3 | q27.3 | 2 | 4 | Gain | TBCCD1 | 110 | T | No |
| 3 | q27.3 | 2 | 4 | Gain | DNAJB11 | 110 | T | No |
| 3 | q27.3 | 2 | 4 | Gain | AHSG | 110 | T | Yes |
| 3 | q27.3 | 2 | 4 | Gain | FETUB | 110 | E/I | Yes |
| 3 | q27.3 | 2 | 4 | Gain | ST6GAL1 | 46 | E/I | Yes |
| 3 | q27.3 | 2 | 4 | Gain | MASP1 | 428 | E/I | No |
| 3 | q27.3 | 3 | 4 | Gain | RTP4 | 148 | T | No |
| 3 | q27.3 | 2 | 4 | Gain | SST | 428 | T | No |
| 3 | q27.3 | 2 | 4 | Gain | FLJ42393 | 191 | T | Yes |
| 3 | q28 | 3 | 4 | Gain | LPP | 191 | E/I | Yes |
| 3 | q28 | 2 | 4 | Gain | TP63 | 142 | E/I | No |
| 3 | q28 | 2 | 4 | Gain | CLDN1 | 203 | T | No |
| 3 | q28 | 2 | 4 | Gain | CLDN16 | 203 | T | No |
| 3 | q28 | 2 | 4 | Gain | TMEM207 | 203 | T | No |
| 3 | q29 | 2 | 4 | Gain | C3orf59 | 396 | E/I | No |
| 3 | q29 | 2 | 4 | Gain | MGC2889 | 396 | T | Yes |
| 3 | q29 | 2 | 4 | Gain | HRASLS | 396 | T | Yes |
| 3 | q29 | 2 | 4 | Gain | ATP13A5 | 396 | E/I | No |
| 3 | q29 | 2 | 4 | Gain | ATP13A4 | 158 | E/I | Yes |
| 3 | q29 | 2 | 4 | Gain | OPA1 | 158 | T | Yes |
| 3 | q29 | 2 | 4 | Gain | GP5 | 97 | E/I | No |
| 3 | q29 | 2 | 4 | Gain | ATP13A3 | 97 | T | Yes |
| 3 | q29 | 2 | 4 | Gain | TM4SF19 | 87 | E/I | Yes |
| 3 | q29 | 2 | 4 | Gain | UBXN7 | 87 | E/I | Yes |
| 3 | q29 | 2 | 4 | Gain | DLG1 | 240 | E/I | Yes |
| 3 | q29 | 2 | 4 | Gain | FYTTD1 | 50 | T | Yes |
| 3 | q29 | 2 | 4 | Gain | LRCH3 | 50 | E/I | Yes |
| 3 | q29 | 2 | 4 | Gain | RPL35A | 91 | E/I | Yes |
| 3 | q29 | 2 | 4 | Gain | IQCG | 91 | E/I | Yes |
| 3 | q29 | 2 | 4 | Gain | LMLN | 91 | T | Yes |
| 4 | q13.3 | 2 | 2 | Gain | SLC4A4 | 46 | E/I | No |
| 11 | p15.1 | 2 | 2 | Gain | NELL1 | 43 | I | No |
| 14 | q13.1 | 2 | 2 | Gain | NPAS3 | 43 | I | Yes |
| 16 | p11.1 | 2 | 2 | Gain | LOC283914 | 277 | T | Yes |
| 21 | p11.2–p11.1 | 2 | 3 | Loss | TPTE | 107 | T | Yes |
| X | p22.33 | 3 | 3 | Gain | DHRSX | 31 | E/I | Yes |
| X | q12 | 2 | 2 | Gain | EDA2R | 91 | E/I | Yes |
| Y | q11.21 | 2 | 2 | Gain | USP9Y | 60 | E/I | No |
129 gains concerned the long arm of chromosome 3 (3q). 123 gains concerned gene coding regions. 75 CNA did not include previously reported polymorphism (Database of Genomic Variants, DGV). Gain of one exon of MDS1 (part of MECOM gene) was recurrently observed in 7 patients (including mosaicism phenomenon)
Chr chromosome, Recurrence number of patients with the same CNA, CN state Copy Number state, gain or loss
Fig. 1.
Schematic representation of region 3q26.2 corresponding to MECOM gene in CD19+ B-cells of 9 patients. We observed a common minimal amplified region of 28 kilobases (85 copy number markers) in 7 patients. This amplification is observed in all the CD19+ B-cells in 6 patients (copy number at 3, CN 3) and in a part of CD19+ B-cells in 1 patient (copy number between 2 and 3 revealing a mosaicism phenomenon)
Discussion
Similar to the described link between aneuploidy, genetic instability and the development of human cancers [11, 12], supernumerary isochromosome 3q could be the cause of chromosomal instability observed in PPBL. Transfer of isochromosome 3q into myoblast cell line caused abnormal cytokinesis, centrosome amplification, aneuploidy and abolished G1 arrest following DNA damage. These observations might be related to an increasing expression of ATR gene located on 3q [13]. Moreover, isochromosome 3q has been implicated in the progression of cervical carcinomas, where cells exhibiting either tetrasomy or aneusomy for chromosomes 3 and 17 increased significantly with disease progression [13–16]. Supernumerary isochromosome 3q could explain binucleated lymphocytes and chromosomal instability observed in PPBL. MECOM abnormalities, particularly the overexpression of EVI1, have been described in the pathogenesis of myeloid neoplasm such as acute myeloid leukemia and myelodysplastic syndrome, especially concerning cell-cycle disorders [17–21]. Furthermore, as observed by Stein et al., EVI1 activation could lead to genetic instability [22]. Even if it has never been observed in lymphoid neoplasm, the potential implication of MECOM in PPBL has to be elucidated.
The link between PPBL and subsequent malignancies remains unclear and the role of tobacco is probably dominant. Majority of our patients (17/18) with subsequent malignancies were chronic smokers. We reported recently a detailed description of 2 heavy smokers patients with subsequent malignancies, UPN57 and UPN71 [23]. Tobacco use is a recognized risk factor in the development of solid tumor, such as pulmonary cancer, and also lymphoma [24]. Therefore, in PPBL, where tobacco consumption is frequent (90 % of our cohort of 150 patients), smoking could represent a confounding factor in interpreting the link between PPBL and subsequent malignancies.
Isochromosome 3q has been described in cell-cycle deregulation, chromosomal instability and progression of cervical cancers. Our cytogenetic and clinical observations lead us to hypothesize that isochromosome 3q in B-cells plays a key role in the physiopathology and evolution of PPBL. Although isochromosome 3q has not been yet identified in tumor cells of subsequent malignancies [23], it could be implicated in chromosomal and genomic instability. This genomic instability could be part of a multi-step process leading to the emergence of a malignant B lymphoproliferation. MECOM gene could be a good candidate to explain these observations and remains to be explored.
Availability of data and materials
All raw data are available from the authors upon request.
Authors’ contributions
HM and XT designed the study. EC and XT wrote the manuscript. EC and HM analyzed SNP arrays data. KC performed SNP arrays. HM analyzed conventional cytogenetic and FISH. EC, JFL and XT examined the patients and collected clinical/biological data. All authors read and approved the final manuscript.
Acknowledgements
We acknowledge all the members of the Groupe Francophone d’Hématologie Cellulaire (GFHC) who participated in this study and followed up PPBL patients.
Competing interests
The authors have nothing to disclose.
Contributor Information
Edouard Cornet, Phone: +33 2 31 06 33 15, Email: cornet-e@chu-caen.fr.
Hossein Mossafa, Email: hmossafa@lab-cerba.com.
Karine Courel, Email: KCourel@lab-cerba.com.
Jean-François Lesesve, Email: jf.lesesve@chu-nancy.fr.
Xavier Troussard, Email: troussard-x@chu-caen.fr.
References
- 1.Gordon DS, Jones BM, Browning SW, Spira TJ, Lawrence DN. Persistent polyclonal lymphocytosis of B lymphocytes. N Engl J Med. 1982;307(4):232–236. doi: 10.1056/NEJM198207223070407. [DOI] [PubMed] [Google Scholar]
- 2.Leclerc M, Lesesve JF, Gaillard B, Troussard X, Tourbah A, Debouverie M, Daliphard S, Delmer A. Binucleated lymphocytes in patients with multiple sclerosis treated with natalizumab. Leukemia lymphoma. 2011. [DOI] [PubMed]
- 3.Mossafa H, Malaure H, Maynadie M, Valensi F, Schillinger F, Garand R, Jung G, Flandrin G, Troussard X. Persistent polyclonal B lymphocytosis with binucleated lymphocytes: a study of 25 cases. Groupe Francais d’Hematologie Cellulaire. Br J Haematol. 1999;104(3):486–493. doi: 10.1046/j.1365-2141.1999.01200.x. [DOI] [PubMed] [Google Scholar]
- 4.Mossafa H, Troussard X, Valensi F, Schillinger F, Maynadie M, Bulliard G, Macintyre E, Flandrin G. Isochromosome i(3q) and premature chromosome condensation are recurrent findings in chronic B-cell lymphocytosis with binucleated lymphocytes. Leukemia Lymphoma. 1996;20(3–4):267–273. doi: 10.3109/10428199609051617. [DOI] [PubMed] [Google Scholar]
- 5.Himmelmann A, Gautschi O, Nawrath M, Bolliger U, Fehr J, Stahel RA. Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD(+)CD27(+) memory B cells. Br J Haematol. 2001;114(2):400–405. doi: 10.1046/j.1365-2141.2001.02938.x. [DOI] [PubMed] [Google Scholar]
- 6.Loembe MM, Neron S, Delage R, Darveau A. Analysis of expressed V(H) genes in persistent polyclonal B cell lymphocytosis reveals absence of selection in CD27+ IgM+ IgD+ memory B cells. Eur J Immunol. 2002;32(12):3678–3688. doi: 10.1002/1521-4141(200212)32:12<3678::AID-IMMU3678>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
- 7.Lawlor E, Murray M, O’Briain DS, Blaney C, Foroni L, Sarsfield P, Condell D, Sullivan F, McCann SR. Persistent polyclonal B lymphocytosis with Epstein-Barr virus antibodies and subsequent malignant pulmonary blastoma. J Clin Pathol. 1991;44(4):341–342. doi: 10.1136/jcp.44.4.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Roy J, Ryckman C, Bernier V, Whittom R, Delage R. Large cell lymphoma complicating persistent polyclonal B cell lymphocytosis. Leukemia Off J Leukemia Soc Am Leukemia Res Fund UK. 1998;12(7):1026–1030. doi: 10.1038/sj.leu.2401040. [DOI] [PubMed] [Google Scholar]
- 9.Mossafa H, Tapia S, Flandrin G, Troussard X. Chromosomal instability and ATR amplification gene in patients with persistent and polyclonal B-cell lymphocytosis (PPBL) Leukemia Lymphoma. 2004;45(7):1401–1406. doi: 10.1080/10428194042000191738. [DOI] [PubMed] [Google Scholar]
- 10.Cornet E, Lesesve JF, Mossafa H, Sebahoun G, Levy V, Davi F, Troussard X. Long-term follow-up of 111 patients with persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes. Leukemia Off J Leukemia Soc Am Leukemia Res Fund UK. 2009;23(2):419–422. doi: 10.1038/leu.2008.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA. 1998;95(23):13692–13697. doi: 10.1073/pnas.95.23.13692. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396(6712):643–649. doi: 10.1038/25292. [DOI] [PubMed] [Google Scholar]
- 13.Smith L, Liu SJ, Goodrich L, Jacobson D, Degnin C, Bentley N, Carr A, Flaggs G, Keegan K, Hoekstra M, et al. Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced G1 arrest. Nat Genet. 1998;19(1):39–46. doi: 10.1038/ng0598-39. [DOI] [PubMed] [Google Scholar]
- 14.Heselmeyer K, Macville M, Schrock E, Blegen H, Hellstrom AC, Shah K, Auer G, Ried T. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosom Cancer. 1997;19(4):233–240. doi: 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
- 15.Heselmeyer K, Schrock E, du Manoir S, Blegen H, Shah K, Steinbeck R, Auer G, Ried T. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA. 1996;93(1):479–484. doi: 10.1073/pnas.93.1.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Olaharski AJ, Sotelo R, Solorza-Luna G, Gonsebatt ME, Guzman P, Mohar A, Eastmond DA. Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. Carcinogenesis. 2006;27(2):337–343. doi: 10.1093/carcin/bgi218. [DOI] [PubMed] [Google Scholar]
- 17.Buonamici S, Chakraborty S, Senyuk V, Nucifora G. The role of EVI1 in normal and leukemic cells. Blood Cells Mol Dis. 2003;31(2):206–212. doi: 10.1016/S1079-9796(03)00159-1. [DOI] [PubMed] [Google Scholar]
- 18.Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ, Beverloo HB, Lowenberg B, Delwel R. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008;111(8):4329–4337. doi: 10.1182/blood-2007-10-119230. [DOI] [PubMed] [Google Scholar]
- 19.Goyama S, Kurokawa M. Evi-1 as a critical regulator of leukemic cells. Int J Hematol. 2010;91(5):753–757. doi: 10.1007/s12185-010-0618-5. [DOI] [PubMed] [Google Scholar]
- 20.Sitailo S, Sood R, Barton K, Nucifora G. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements. Leukemia Off J Leukemia Soc Am Leukemia Res Fund UK. 1999;13(11):1639–1645. doi: 10.1038/sj.leu.2401585. [DOI] [PubMed] [Google Scholar]
- 21.Metais JY, Dunbar CE. The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. Mol Ther. 2008;16(3):439–449. doi: 10.1038/sj.mt.6300372. [DOI] [PubMed] [Google Scholar]
- 22.Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Kramer A, Schwable J, Glimm H, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16(2):198–204. doi: 10.1038/nm.2088. [DOI] [PubMed] [Google Scholar]
- 23.Méar J, Troussard X, Salaün V, Mossafa H, Damaj G, Le Naourès C, Galateau-Sallé F, Cornet E. Occurrence of non-hodgkin lymphoma after the diagnosis of persistent polyclonal B-cell lymphocytosis. J Leuk. 2015;3(175):2. [Google Scholar]
- 24.Nieters A, Deeg E, Becker N. Tobacco and alcohol consumption and risk of lymphoma: results of a population-based case-control study in Germany. Int J Cancer. 2006;118(2):422–430. doi: 10.1002/ijc.21306. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All raw data are available from the authors upon request.